| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
74,175,000 |
| Market
Cap: |
1.98(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$18.33 - $27.25 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 1065 |
| Guru Rank Value : 0 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Pacira BioSciences is a holding company. Through its subsidiaries, Co. is focused on non-opioid pain management. Co. has three commercialized non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting, local analgesic approved for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, corticosteroid injection indicated for the management of OA knee pain; and ioveradeg®, a handheld device for delivering immediate, long-acting, drug-free pain control using controlled doses of cold temperature to a targeted nerve.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
20,976 |
| Total Buy Value |
$0 |
$0 |
$0 |
$256,518 |
| Total People Bought |
0 |
0 |
0 |
5 |
| Total Buy Transactions |
0 |
0 |
0 |
7 |
| Total Shares Sold |
41,020 |
48,286 |
69,119 |
211,037 |
| Total Sell Value |
$988,553 |
$1,168,825 |
$1,708,433 |
$5,992,206 |
| Total People Sold |
2 |
4 |
6 |
9 |
| Total Sell Transactions |
4 |
6 |
9 |
20 |
| End Date |
2025-09-14 |
2025-06-13 |
2024-12-13 |
2023-12-14 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Cross Shawn |
Chief Financial Officer |
• – – |
2025-12-10 |
4 |
AS |
$25.14 |
$228,875 |
D/D |
(9,104) |
56,250 |
|
4% |
|
| Cross Shawn |
Chief Financial Officer |
• – – |
2025-12-10 |
4 |
OE |
$16.45 |
$149,761 |
D/D |
9,104 |
65,354 |
|
- |
|
| Cross Shawn |
Chief Financial Officer |
• – – |
2025-12-09 |
4 |
AS |
$25.03 |
$397,877 |
D/D |
(15,896) |
56,250 |
|
6% |
|
| Cross Shawn |
Chief Financial Officer |
• – – |
2025-12-09 |
4 |
OE |
$16.45 |
$261,489 |
D/D |
15,896 |
72,146 |
|
- |
|
| Slonin Jonathan |
Chief Medical Officer |
• – – |
2025-11-17 |
4 |
AS |
$24.09 |
$95,396 |
D/D |
(3,960) |
178,367 |
|
10% |
|
| Cross Shawn |
Chief Financial Officer |
• – – |
2025-11-10 |
4 |
AS |
$22.09 |
$266,405 |
D/D |
(12,060) |
56,250 |
|
14% |
|
| Cross Shawn |
Chief Financial Officer |
• – – |
2025-10-31 |
4 |
D |
$21.38 |
$143,032 |
D/D |
(6,690) |
68,310 |
|
- |
|
| Ceesay Abraham |
Director |
– • – |
2025-09-04 |
4 |
AS |
$27.19 |
$64,005 |
D/D |
(2,354) |
9,039 |
|
-2% |
|
| Bigal Marcelo |
Director |
– • – |
2025-08-07 |
4 |
S |
$23.67 |
$116,267 |
D/D |
(4,912) |
11,393 |
|
-11% |
|
| Slonin Jonathan |
Chief Medical Officer |
• – – |
2025-08-01 |
4 |
D |
$22.07 |
$6,952 |
D/D |
(315) |
182,327 |
|
- |
|
| Yang Michael J. |
Director |
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
6,163 |
13,393 |
|
- |
|
| Froimson Mark |
Director |
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
6,163 |
20,636 |
|
- |
|
| Brege Laura |
Director |
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
6,163 |
23,715 |
|
- |
|
| Christie Christopher |
Director |
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
6,163 |
16,654 |
|
- |
|
| Bigal Marcelo |
Director |
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
6,163 |
16,305 |
|
- |
|
| Ceesay Abraham |
Director |
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
6,163 |
11,393 |
|
- |
|
| Kronenfeld Mark A. |
Director |
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
9,999 |
34,901 |
|
- |
|
| Young Alethia |
Director |
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
6,163 |
11,393 |
|
- |
|
| Dunker Kristen Marie |
Chief Administrative Officer |
• – – |
2025-06-04 |
4 |
S |
$26.24 |
$377,226 |
D/D |
(14,376) |
161,574 |
|
17% |
|
| Riker Lauren Bullaro |
Senior Vice President, Finance |
• – – |
2025-06-04 |
4 |
S |
$26.21 |
$146,208 |
D/D |
(5,578) |
59,564 |
|
17% |
|
| Slonin Jonathan |
Chief Medical Officer |
• – – |
2025-06-03 |
4 |
D |
$26.40 |
$134,218 |
D/D |
(5,084) |
181,960 |
|
- |
|
| Dunker Kristen Marie |
Chief Administrative Officer |
• – – |
2025-06-03 |
4 |
D |
$26.40 |
$162,677 |
D/D |
(6,162) |
175,950 |
|
- |
|
| Riker Lauren Bullaro |
Senior Vice President, Finance |
• – – |
2025-06-03 |
4 |
D |
$26.40 |
$89,074 |
D/D |
(3,374) |
65,142 |
|
- |
|
| Dunker Kristen Marie |
Chief Administrative Officer |
• – – |
2025-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
79,200 |
182,112 |
|
- |
|
| Lee Frank D. |
Chief Executive Officer |
• • – |
2025-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
350,000 |
448,409 |
|
- |
|
559 Records found
|
|
Page 1 of 23 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.39 (1.48%) 
